Aug. 4, 2011
/PRNewswire/ -- The Female Health Company (NASDAQ- FHCO - News) announced today that Lucie van Mens has been appointed Director of Program Development and Support. Dr.
has significant experience in the field of HIV/AIDS prevention. She most recently held the position as Coordinator of Universal Access to Female Condoms (UAFC), a partnership between Oxfam Novib, i+solutions, Rutgers WPF and the Dutch Ministry of Foreign Affairs in cooperation with social marketing organizations in African countries. In this position, she successfully headed the advocacy group in demanding improved access to female condoms through increased funding for programming and research and development of female condoms. Her involvement in public health, focusing on prevention of STI (sexually transmitted infections) and HIV/AIDS dates back to 1995. During that period, positions held included that of program manager of STOP AIDS NOW!, a partnership between four Dutch organizations for international cooperation (Cordaid, Hivos, ICCO, Oxfam Novib and the AIDS Fund) and Program Manager, STI and AIDS Prevention – Soa Aids Nederland.
earned her MA in Social History from
. She earned MBA certificates in Finance, Marketing, Logistics and Organization and a PhD in Organization and Management Studies from the Rotterdam School of Management,
. Dr. van Mens spent the earlier portion her career in the field of education.
"We are very pleased to have Dr.
join us, bringing her unique perspective regarding STI and HIV/AIDS prevention. She has a proven track record of success in both raising awareness of the unmet need for female condoms globally and expanding women's access to them. Her experiences in programming, social marketing, fund-raising and management will be a valuable addition to the Company's on-going efforts," said
, Vice President and General Manager, to whom she will be reporting.
Female Health Company
The Female Health Company, based in
, manufactures and markets the
FC2 Female Condom® (FC2),
which is available in the U.S. and about 120 other countries globally. The Company owns certain worldwide rights to the
FC2 Female Condom
®, including patents that have been issued in the U.S.,
the People's Republic of China
, and pending in various countries.
The FC2 Female Condom®
is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared
for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.
For more information about The Female Health Company visit the Company's website at
. If you would like to be added to the Company's e-mail alert list, please send an e-mail to
SOURCE The Female Health Company